MMP-7 Buffer Composition for Aggregate Monomerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
MMP-7 aggregates form under isotonic conditions with monovalent cation compounds, leading to adsorption to manufacturing apparatus and container walls, hindering large-scale production and medicinal use.
Innovation Solution
Treat MMP-7 aggregates with a solution containing a low concentration of monovalent cation chloride, such as sodium chloride or potassium chloride, and incorporate sugars or sugar alcohols to suppress aggregate formation and adsorption, using a Tris buffer at pH 6 to 8.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MMP-7 is stored in a solution with monovalent cation compound at isotonic concentration (150 mM or more), then the osmotic pressure is appropriate for medicinal use, but MMP-7 forms aggregates and adsorbs to container walls
Solution Approach 1:
The patent changes the concentration parameter of monovalent cation compounds from conventional isotonic levels (150 mM or more) to low concentrations (130 mM or less), which fundamentally alters the solution chemistry to prevent MMP-7 aggregate formation while maintaining acceptable osmotic pressure for medicinal use
Solution Approach 2:
The patent introduces sugar alcohols or sugars as intermediary substances that mediate between the conflicting requirements of osmotic pressure and protein stability. These additives protect MMP-7 from aggregation at low monovalent cation concentrations while contributing to the overall osmotic balance
2Stability of the object's composition
If MMP-7 aggregates are formed under isotonic conditions, then the solution is stable for storage, but MMP-7 adsorbs to manufacturing apparatus and container walls
Solution Approach 1:
The patent changes the monovalent cation concentration parameter to low levels (130 mM or less), which simultaneously achieves solution stability and prevents adsorption losses by altering the electrochemical environment at protein-surface interfaces
Solution Approach 2:
Sugar alcohols or sugars act as intermediary protective agents that prevent direct interaction between MMP-7 and container surfaces, reducing adsorption losses while maintaining solution stability during storage and processing
3Manufacturing precision
If conventional purification methods are used for MMP-7, then the purification process is established, but productivity and recovery efficiency are low
Solution Approach 1:
The patent changes the monovalent cation concentration parameter throughout the purification process to low levels (130 mM or less), which prevents aggregate formation and maintains MMP-7 in a monomeric state, thereby improving recovery efficiency while maintaining purification quality
Solution Approach 2:
The patent applies monomerization treatment using low monovalent cation solutions as a preliminary step before conventional purification procedures, ensuring that MMP-7 remains in a stable monomeric form that is more amenable to efficient purification and recovery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances MMP-7 productivity and maintains enzymatic activity, preventing adsorption to containers, thus providing a high-quality MMP-7 preparation for medicinal use.
Implementation Method 1
MMP-7 aggregates are dissociated to form monomers by the treatment with a solution such as a Tris buffer (pH 6 to 8) comprising a low concentration of a monovalent cation chloride (sodium chloride and potassium chloride)
Implementation Method 2
MMP-7 is adsorbed to gel in an apparatus normally used for the manufacture of proteins or their preparations or to a container such as a vial normally used for storage of preparations
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.